

Evaluation of Endotherapia and Palmitoylethanolamide (PEA) for Amyotrophic Lateral Sclerosis and Other Conditions

1. Introduction to Amyotrophic Lateral Sclerosis (ALS) and Therapeutic Landscape

Amyotrophic Lateral Sclerosis (ALS) represents a devastating and rapidly progressive neurodegenerative disorder. It is characterized by the relentless degeneration of motor neurons within the brain and spinal cord, leading to profound and progressive muscle weakness, paralysis, and ultimately, respiratory failure. The prognosis for individuals diagnosed with ALS is grim, with a median survival typically ranging from two to five years from symptom onset.

The current therapeutic landscape for ALS remains significantly limited, underscoring a substantial unmet medical need. Existing approved treatments, such as Riluzole and Edaravone, offer only modest benefits, typically extending life expectancy by a few months, as noted for Riluzole which offers 3-6 months.¹ This critical scarcity of effective interventions fuels an urgent and continuous pursuit of novel therapeutic strategies. Research efforts are increasingly focused on understanding and targeting key pathological features of ALS, including neuroinflammation, oxidative stress, and mitochondrial dysfunction, which are recognized as central drivers of disease progression.

2. Endotherapia (GEMALS): A Detailed Review

Endotherapia, also known by the designations "multivalent nanotherapy" or GEMALS, is a therapeutic approach promoted by a French research group. It is advertised as a "new therapeutic approach to chronic conditions, including auto-immune, neurodegenerative" diseases.²

2.1. Description and Composition

Endotherapia is presented as a "tailor-made" combination therapy. Its composition includes functional

polypeptides, fatty acids, free radical scavengers, and amino acids, all of which are reportedly linked to a non-immunogenic chain of poly-L-Lysine (PLL).¹ This PLL conjugation is purported to enhance the stability of the active components, reducing their degradation and improving their permeability within the body, thereby increasing their half-life.² Proponents of Endotherapia assert that the specific therapeutic cocktail remains largely consistent across the "hundreds" of individuals with ALS (PALS) they claim to have treated.²

The specific components identified within the Endotherapia cocktail for ALS patients are detailed in Table 1. This complex, multi-component nature is a defining characteristic of the therapy, aiming for a "multivalent" effect. Understanding these specific constituents is crucial for any informed discussion of its potential mechanisms and interactions, especially concerning the individual properties of its fatty acid components.

Table 1: Key Components of Endotherapia (GEMALS) Cocktail for ALS²

| Category | Specific Components (linked to PLL) |
|--------------------------------------|-------------------------------------|
| Fatty acids, sterols and derivatives | Oleic-PLL-Thioctic |
| | Oleic-PLL-Palmitic |
| | Oleic-PLL-Linoleic |
| | Lauric-PLL-Caprylic |
| | Cholesterol-PLL-Oleic |
| Anti-oxidants and scavengers | Pantothenic-PLL |
| | Oleic-PLL-Coenzyme Q10 |
| | Ascorbic Acid-PLL |
| | L-Glutathione-G-PLL |
| Amino acids and derivatives | L-Methionine-GA-PLL |
| | L-Cysteine-GA-PLL |
| | L-Methionine-G-PLL |
| | Agmatine-G-PLL |

2.2. Proposed Mechanisms of Action

The proposed mechanism of action for Endotherapia is intricate and centers on the identification and targeting of circulating antibodies directed against specific self-antigens and self-antigens modified by free radicals.¹ Proponents suggest that certain non-pathological bacteria, such as

E. coli and cyanobacteria, are implicated in triggering ALS through inflammatory or autoimmune processes, and the therapy is designed to counteract these perceived triggers.²

However, a critical examination reveals significant concerns regarding this foundational premise. Independent reviews explicitly state that there is no scientific evidence to support the claim that bacteria can trigger ALS through inflammation or autoimmunity.² Furthermore, the references cited by Endotherapia's proponents do not substantiate the involvement of such bacteria in ALS pathophysiology.² This fundamental lack of support for the underlying mechanistic hypothesis raises serious questions about the rationale for Endotherapia's therapeutic approach in ALS. If the very basis of the mechanism—the role of specific bacterial triggers in ALS—is unsubstantiated, then the entire therapeutic strategy is undermined, regardless of the individual properties of its components.

The PLL conjugation within Endotherapia is hypothesized to enhance the permeability and reduce the degradation of the active components.² Some fatty acid-PLL conjugates, such as lauryl-PLL, have demonstrated

in vitro antibacterial activity, suggesting a potential antimicrobial aspect to the therapy.³ This aspect, however, does not address the primary, unsubstantiated claim regarding bacterial involvement in ALS.

2.3. Preclinical Evidence in ALS Models

One published study reported that Endotherapia (GEMALS) might delay disease onset and prolong survival in the G93A mutant SOD1 rat model of ALS.¹ This study also claimed improvements in electromyographic parameters in these animals.¹

Despite these reported findings, the preclinical data are subject to considerable skepticism due to significant methodological shortcomings. Independent assessments highlight "multiple methodological flaws according to published guidelines" in this study.² These flaws include a small sample size, the initiation of treatment pre-symptomatically, and a failure to blind raters.² Treating animals pre-symptomatically in a rapidly progressive disease model like SOD1 rats can artificially inflate perceived benefits, as the disease has not yet fully manifested. The absence of blinding introduces a substantial risk of observer bias, potentially leading to an overestimation of treatment effects. Furthermore, a small sample size compromises the statistical power and reliability of the findings. Such methodological deficiencies mean that the reported preclinical benefits are highly unreliable and, as often observed in ALS research, are unlikely to translate effectively to human treatments.⁴

2.4. Clinical Evidence in ALS Patients

Clinical reports on Endotherapia in ALS patients have also faced severe criticism. One published trial involved 12 participants who received treatment for periods ranging from 3 to 72 months, utilizing the ALSAQ40 (ALS Assessment Questionnaire) to measure disease severity and progression.² A subsequent study, detailed in review articles, involved 31 individuals with ALS and reported benefits on their ALSAQ40 scores when compared to a "worldwide reference" population.¹ Proponents claimed a deceleration of disease in 83.87% of patients and a remarkable increase in mean life expectancy by 38 months.¹

However, independent expert bodies, such as ALS Untangled, have identified profound flaws in these clinical reports.² The ALSAQ40, while a measure of quality of life, is not considered an appropriate primary measure of ALS progression, as it is not tightly correlated with motor function or survival.² The reliance on an unspecified "worldwide reference" population for comparison is highly problematic; ALS progression is influenced by demographics and disease characteristics, necessitating careful matching for historical control groups, which was not evident in these studies.⁴ Furthermore, there was no clear systematic screening for or reporting of adverse events.⁴ Consequently, ALS Untangled concluded that "the data on Endotherapia in PALS have so many problems that we believe they are uninterpretable" and explicitly does not recommend its use for ALS.⁴

While subjective patient reports exist, such as one individual claiming clearer speech, improved speed, stronger facial muscles, and improving leg strength after seven months of treatment², these anecdotal accounts lack independent validation and scientific rigor. It is also notable that no individuals with ALS in the online community PatientsLikeMe reported taking Endotherapia.²

The critical assessment by ALS Untangled is summarized in Table 2, providing a standardized evaluation of the evidence for Endotherapia as an ALS treatment. The consistently low grades assigned by this independent review body underscore the severe deficiencies in the supporting evidence.

Table 2: ALS Untangled TOE Grades for Endotherapia as an ALS Treatment²

| Grade | Explanation |
|------------------------|---|
| Mechanism: D | Endotherapia may act on a biological mechanism, but it is not clear this mechanism is relevant in ALS. This ability has never been convincingly demonstrated. |
| Pre-clinical: C | One flawed publication reports benefit in an ALS rat model. |
| Cases: D | Subjective report of benefit without independently validated diagnosis or benefits. |
| Trials: D | One or more published reports of benefit in a flawed trial. |
| Risks: U | There has been no clear systematic safety monitoring of PALS on Endotherapia. |

The claims made by proponents of Endotherapia, particularly those suggesting a "curative effect" or a "mean life expectancy increase by 38 months"¹, are not supported by rigorous, independently verified data. In the context of a rapidly progressive and fatal disease like ALS, where patients and their families are often desperate for effective treatments, unsubstantiated claims of significant benefit raise serious ethical concerns. Such assertions can lead patients to pursue expensive, unproven therapies, potentially diverting resources from or delaying access to evidence-based care, and fostering false hope without adequate safety monitoring.

2.5. Evidence in Other Conditions

Endotherapia is also advertised for the treatment of other chronic conditions, including multiple sclerosis (MS) and rheumatoid arthritis.¹ For MS, one source describes a new therapeutic approach, also called Endotherapia (GEMSP), claiming a 24.5% improvement in the Expanded Disability Status Scale (EDSS) score when compared to a "worldwide reference" group.³ This approach, similar to the ALS formulation, involves a "tailor-made" combination of small molecules linked to PLL.³

The description of Endotherapia's application in Multiple Sclerosis mirrors the problematic methodology observed in the ALS studies, particularly the use of an ill-defined "worldwide reference" group for comparison. This consistent pattern of methodological weaknesses—such as reliance on historical controls without proper matching and a lack of systematic safety reporting—across the claimed applications of Endotherapia suggests a systemic issue in the research design and reporting by its proponents. This consistency further reinforces the overall skepticism regarding the validity of Endotherapia's reported benefits, irrespective of the specific chronic condition it purports to treat.

2.6. Safety Profile and Regulatory Status

A major concern regarding Endotherapia is the absence of comprehensive safety data. ALS Untangled explicitly states that "there has been no clear systematic safety monitoring of PALS on Endotherapia".² This critical lack of safety oversight results in an "U" (Unknown) grade for risks in independent assessments.² Without systematic safety monitoring, the full spectrum, frequency, and severity of potential adverse events associated with Endotherapia remain undetermined. This is particularly troubling for a complex, "tailor-made" cocktail administered over potentially long durations. The inability to adequately assess the risk-benefit profile due to insufficient safety data makes informed clinical decision-making impossible and poses a significant patient safety concern.

3. Palmitoylethanolamide (PEA): A Detailed Review

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that is naturally synthesized within the body in response to various physiological stressors, including injury and inflammation.⁵ It is also found in trace amounts in certain foods, such as egg yolks and peanuts.⁶ As a member of the N-acylethanolamine family, PEA plays a vital role in maintaining cellular homeostasis during periods of stress and inflammation.⁸ Its synthesis occurs on demand within the lipid bilayer, and its concentrations are known to increase in response to tissue injury and cellular stress, indicating its function as an intrinsic protective and homeostatic agent.⁸

It is important to clarify that Palmitoylethanolamide (PEA) is distinct from "Pulseless Electrical Activity (PEA)," a term used in the context of cardiac arrest algorithms.⁹ These two terms refer to entirely unrelated concepts, and the latter is not pertinent to this report's focus on therapeutic agents.

3.2. Mechanisms of Action (Anti-inflammatory, Analgesic, Neuroprotective)

PEA primarily exerts its diverse effects through its interaction with the peroxisome proliferator-activated receptor alpha (PPAR- α), which it binds to and activates.⁵ PPAR- α activation is integral to regulating lipid metabolism and inflammatory processes, notably by promoting fatty acid oxidation and reducing the production of pro-inflammatory cytokines.⁸

While PEA was initially thought to act as a direct agonist for the type 2 cannabinoid receptor (CB2), it is now understood that PEA does not directly bind to cannabinoid receptors.⁵ Instead, PEA indirectly modulates the endocannabinoid system by inhibiting fatty acid amide hydrolase (FAAH), an enzyme responsible for degrading anandamide (AEA). This inhibition leads to increased levels of AEA, which in turn enhances the activation of both CB1 and CB2 cannabinoid receptors, contributing to its anti-inflammatory and analgesic actions through what is known as the "entourage effect".⁸

PEA has demonstrated potent anti-inflammatory effects in preclinical models, reducing the levels of key pro-inflammatory cytokines such as IL-1 β , TNF α , and IL-6, while simultaneously increasing the anti-inflammatory cytokine IL-10.⁵ It has also been shown to reduce caspase 3 activation and lipid peroxidation.⁵ Beyond PPAR- α and indirect cannabinoid modulation, PEA interacts with other molecular targets, including GPR55 and TRPV1. The activation of TRPV1, a receptor involved in pain perception and neuroinflammation, leads to the desensitization of sensory neurons, thereby contributing to its pain-reducing effects. Furthermore, PEA stabilizes mast cells, which helps to mitigate allergic and inflammatory responses.⁸

PEA also possesses neuroprotective properties, safeguarding neuronal cells from oxidative damage and neurodegeneration.⁵ Its endogenous concentrations are known to increase in various neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.⁸ This multifaceted and well-characterized mechanism of action, supported by consistent descriptions across multiple sources⁵, provides a strong biological rationale for PEA's observed therapeutic effects in a range of inflammatory and pain conditions. This contrasts sharply with the vague and poorly supported mechanistic claims associated with Endotherapia, indicating a higher level of scientific rigor in PEA research.

3.3. Preclinical Evidence in Neurodegenerative Models

In preclinical studies, PEA has consistently exhibited strong anti-inflammatory and neuroprotective effects across various models.⁵ For instance, in models of stroke, a co-ultramicronized formulation of PEA with luteolin demonstrated superior outcomes compared to PEA alone. This combination effectively prevented increases in TNF α and IL-1 β , improved neurobehavioral functions, and reduced apoptotic cell death, inflammation, and edema.⁵ These findings underscore PEA's potential in mitigating neuroinflammatory processes and neuronal damage.

3.4. Clinical Evidence in ALS Patients

Research into PEA's potential role in Amyotrophic Lateral Sclerosis (ALS) has yielded promising preliminary findings.

Direct Effect on Muscle Function: Palmitoylethanolamide (PEA) has been shown to reduce the rundown of acetylcholine receptor (AChR) currents in ALS muscle, suggesting a direct beneficial effect on muscle physiology. This effect was observed in muscle membranes from both ALS patients and denervated (non-ALS) control patients, with PEA selectively influencing the rundown of ACh currents in ϵ -AChRs.¹²

Pulmonary Function: Clinically, a study involving a cohort of 76 ALS patients indicated that those treated with PEA experienced a slower decline in their forced vital capacity (FVC) over time compared to untreated ALS patients. This suggests that PEA may enhance pulmonary function in individuals with ALS.¹² This observation is supported by a single case report where PEA appeared to improve muscle force and respiratory efficacy in an ALS patient.¹²

NCT02645461 Clinical Trial (PEA and Riluzole in ALS):

A significant ongoing investigation into PEA's role in ALS is the randomized controlled blinded study known as AchALS, registered under ClinicalTrials.gov ID NCT02645461. This trial is sponsored by the University of Roma La Sapienza.¹³

The primary objective of this study is to determine if PEA can reduce the rundown of AChRs currents in ALS muscle and, consequently, modify the clinical and electrophysiological parameters of ALS patients.¹³ The study design involves randomizing patients with sporadic ALS into two treatment groups: one receiving Riluzole alone, and the other receiving Riluzole combined with ultramicronized PEA (Normast 600 mg, 2 sachets/day).¹³ The trial anticipates enrolling 50 patients, with randomization stratified by the type of clinical onset (bulbar versus spinal).¹³

Key outcome measures, assessed over a six-month period, include changes from baseline in pulmonary capacity (measured by FVC%) as the primary outcome.¹³ Secondary outcome measures encompass changes in acetylcholine receptor (AChR) currents (evaluated using voltage-clamp intracellular recordings in oocytes transplanted with ALS muscle membranes), changes in muscle strength (assessed via the Medical Research Council (MRC) scale score), and changes in electrophysiological parameters (specifically, compound muscle action potentials (CMAP) from the right ulnar and phrenic nerves).¹³

Eligibility criteria for participation include a diagnosis of ALS according to the El-Escorial criteria, age over 18 years,

an ALS Functional Rating Scale-Revised (ALSFRS-R) score greater than 20, a Forced Vital Capacity (FVC) greater than 30%, and current treatment with Riluzole.¹³ Exclusion criteria include other motor neuron diseases, participation in experimental treatments within the preceding three months, pregnancy or breastfeeding, contraindications to Riluzole, patients undergoing tracheostomy or enteral/parenteral feeding, and severe psychiatric disorders.¹³ This trial represents a rigorous scientific effort to validate PEA's role in ALS, and its outcomes will be critical for future therapeutic directions.

Table 4: Design and Interventions of Clinical Trial NCT0264561 (PEA and Riluzole in ALS)¹³

| Aspect | Details |
|----------------------------|--|
| ClinicalTrials.gov ID | NCT02645461 |
| Sponsor | University of Roma La Sapienza |
| Last Update Posted | 2016-01-05 |
| Study Objective | To understand if PEA can reduce AChRs currents in ALS muscle and modify clinical/electrophysiological parameters. |
| Study Design | Randomized controlled blinded study, Parallel Assignment. |
| Interventions | Active Comparator: Riluzole (50 mg twice daily) Experimental: Riluzole (50 mg twice daily) + Ultramicronized PEA (600 mg twice daily) |
| Expected Enrollment | 50 patients |
| Patient Groups | Sporadic ALS patients, stratified by clinical onset (bulbar vs. spinal). |
| Primary Outcome Measure | Changes from baseline in pulmonary capacity (FVC%) at 6 months. |
| Secondary Outcome Measures | Changes in AChR currents, muscle strength (MRC score), electrophysiological parameters (CMAP) at 6 months. |
| Key Inclusion Criteria | ALS diagnosis (El-Escorial), age >18, ALSFRS-R >20, FVC >30%, Riluzole treatment. |
| Key Exclusion Criteria | Other motor neuron diseases, recent experimental treatments, pregnant/breast-feeding, contraindications to Riluzole, tracheostomy/enteral feeding, severe psychiatric disorders. |

3.5. Clinical Evidence in Other Conditions

PEA has demonstrated a broad spectrum of therapeutic potential beyond ALS, particularly in conditions characterized by pain and inflammation.

Chronic and Neuropathic Pain: PEA has shown significant efficacy in reducing pain across various chronic and neuropathic pain conditions.⁵ A 2017 meta-analysis, which included 10 randomized clinical trials with 786 patients, found PEA to be associated with a significantly greater pain reduction compared to inactive control conditions.⁵ An observational study involving 610 patients with chronic pain of different origins also reported a significant decrease in mean pain intensity following PEA treatment.⁵

Osteoarthritis: Oral administration of PEA appears to reduce pain and improve function in individuals with osteoarthritis.⁷

Stroke: An open-label clinical study conducted in 250 stroke patients reported that a combination of co-ultramicronized PEA (700 mg) and luteolin (70 mg), administered for 60 days, significantly improved both cognitive function and muscle spasticity.⁵

Autism: A case study involving a 10-year-old boy treated with co-ultramicronized PEA-LUT (Glialia®) for one year demonstrated significantly improved behavioral outcomes, including progress in cognitive and sociability behaviors.⁵

Endometriosis: An open-label pilot study revealed that women taking ultra-micronized PEA and polydatin for 90 days experienced relief in chronic pelvic pain, reduced menstrual cramping, improved intimacy, and an overall enhancement in quality of life.⁶ A subsequent systematic review and meta-analysis further corroborated PEA's role in reducing chronic pain symptoms across a wide range of conditions, including endometriosis.⁶

Frontotemporal Dementia (FTD): A Phase 2 randomized, double-blind, placebo-controlled trial involving 48 patients with probable FTD showed promising results. Treatment with co-ultramicronized PEA combined with luteolin (700 mg + 70 mg twice daily) for 24 weeks led to a slower decline in cognitive and functional symptoms compared to placebo, suggesting potential efficacy in slowing FTD progression.¹⁴

Vascular Injury: In a model of vascular damage, a combination of PEA and Polydatin effectively reduced inflammation and oxidative stress.¹⁵ Polydatin, a natural precursor of resveratrol, contributes antioxidant activity that PEA itself lacks directly, highlighting a synergistic effect when combined.¹⁵

The diverse clinical applications and observed efficacy of PEA across multiple conditions, as summarized in Table 3, demonstrate the breadth of its therapeutic potential beyond ALS. This reinforces its established anti-inflammatory and analgesic properties, which provide a plausible biological basis for its neuroprotective role under investigation in ALS.

Table 3: Summary of Clinical Evidence for Palmitoylethanolamide (PEA) in Various Conditions⁵

| Condition | Key Findings/Observed Benefits | Study Type/Strength of Evidence | Key Combinations (if applicable) |
|-----------|--------------------------------|---------------------------------|----------------------------------|
| | | | |

| | | | |
|-------------------------------|--|--|------------------------------------|
| Chronic Pain | Significant pain reduction | Meta-analyses (10 RCTs), Observational studies | PEA alone, PEA + Alpha-Lipoic Acid |
| Neuropathic Pain | Significant pain reduction | Meta-analyses (10 RCTs), Observational studies | PEA alone, PEA + Alpha-Lipoic Acid |
| Osteoarthritis | Reduced pain, improved function | Clinical studies (possibly effective) | PEA alone |
| Stroke | Improved cognitive function, reduced muscle spasticity | Open-label clinical study | PEA + Luteolin |
| Autism | Improved behavioral, cognitive, and sociability behavior | Case study | PEA + Luteolin |
| Endometriosis | Reduced chronic pelvic pain, menstrual cramping, improved intimacy, improved QoL | Open-label pilot study, Systematic review & meta-analysis | PEA + Polydatin |
| Frontotemporal Dementia (FTD) | Less decline in cognitive and functional symptoms | Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial | PEA + Luteolin |
| Vascular Injury | Reduced inflammation and oxidative stress | Preclinical model | PEA + Polydatin |
| ALS (preliminary) | Reduced rundown of AChRs currents, enhanced pulmonary function | Cohort study, Case report | PEA alone (in these observations) |

3.6. Safety Profile and Dosing

PEA is generally considered well tolerated and is classified as "possibly safe" when taken orally for durations up to 3 months.⁷ Minimal side effects have been reported, with nausea occurring in some individuals.⁷ However, there is currently insufficient reliable information regarding its safety for use beyond 3 months, or during pregnancy and breastfeeding.⁷ For children aged 4-17 years, PEA has been used at doses of 600 mg daily for up to 3 months and is considered possibly safe within this context.⁷

Common oral doses for adults typically range from 300-1200 mg daily, administered for periods of 2-12 weeks.⁷ The most effective forms of PEA studied include ultra-micronized PEA (umPEA) and formulations combined with polydatin.⁶ Co-ultramicronized PEA-luteolin (e.g., Glialia[®]) is also a notable formulation.⁵ It has been observed that the therapeutic benefits of PEA tend to accumulate over time, with many patients experiencing noticeable improvements within the first two months and further gains with continued use.⁶ For enhanced efficacy, PEA is often considered most effective when integrated with other supportive therapies, such as pelvic floor physical therapy, anti-inflammatory nutrition, nervous system regulation techniques, and hormone and detox pathway

support.⁶

4. Assessment of Combined Use of Endotherapia and Palmitoylethanolamide (PEA)

4.1. Analysis of Literature for Reported Combined Use

A comprehensive review of the available research material reveals a complete absence of any direct or indirect evidence, studies, or mentions concerning the combined use of Endotherapia (GEMALS) and Palmitoylethanolamide (PEA) for treating Amyotrophic Lateral Sclerosis or any other medical condition. This is the most significant finding directly addressing the core of the user's query.

While PEA is currently being investigated in combination with Riluzole for ALS in a formal clinical trial (NCT02645461)¹³ and has been studied in combination with other compounds such as luteolin or polydatin for various conditions⁵, Endotherapia's components are consistently described as a specific, proprietary cocktail. There is no indication within the provided literature that PEA is a constituent of Endotherapia or that it has ever been co-administered with Endotherapia as a combined therapy. This represents a critical research gap, signifying not merely a lack of positive findings, but a complete void in the scientific literature regarding this specific combination. Consequently, there is no scientific basis to discuss their combined effects, potential synergies, or safety when co-administered. Any discussion of their combined use would be purely speculative and entirely unsupported by the existing evidence.

4.2. Consideration of Potential Theoretical Interactions

Given the complete absence of direct evidence regarding their combined use, any discussion of theoretical interactions between Endotherapia and PEA remains highly speculative. However, an examination of their individual components and mechanisms allows for some hypothetical considerations.

Endotherapia's complex composition includes various fatty acids, notably Oleic-PLL-Palmitic and FarCys-PLL-Palmitic.² Palmitic acid, a saturated fatty acid, is known to induce pro-inflammatory responses and neurotoxicity.¹⁶ It activates NF-κB and inflammasome pathways, leading to an increase in pro-inflammatory cytokines such as TNF-α and IL-1β.¹⁹ While Endotherapia also contains Oleic-PLL², which has demonstrated the capacity to mitigate palmitic acid's neuroinflammatory potential¹⁶, the overall inflammatory balance and net effect

of the entire Endotherapia cocktail are unclear.

In stark contrast, PEA is a well-established anti-inflammatory and neuroprotective agent. Its primary mechanisms involve PPAR- α activation and modulation of the endocannabinoid system, both of which lead to a reduction in pro-inflammatory cytokines.⁵ The inclusion of potentially pro-inflammatory palmitic acid within Endotherapia could theoretically conflict with the anti-inflammatory mechanisms of PEA if these two therapies were combined. This highlights a potential for antagonism or, at the very least, a complex interaction that would necessitate careful study. A simple combination might not lead to synergistic or even additive benefits, and could potentially result in reduced efficacy or unpredictable outcomes.

Furthermore, the poly-L-Lysine (PLL) component of Endotherapia is intended to improve the permeability and half-life of its conjugated molecules.² While PLL can function as a delivery system²⁰, the specific impact of this conjugation on the bioavailability of Endotherapia's components, and how this might interact with PEA's absorption or distribution, remains unknown. This theoretical conflict underscores the necessity for direct, rigorous research if such a combination were ever considered, rather than assuming benefit based on the individual components.

5. Critical Evaluation of the Evidence Base

A critical evaluation reveals a stark disparity in the scientific rigor and trustworthiness of the evidence supporting Endotherapia versus Palmitoylethanolamide (PEA).

For **Endotherapia**, the evidence base in ALS is critically weak. Preclinical studies are fundamentally flawed by methodological shortcomings, including small sample sizes, treatment initiation prior to symptom onset, and a lack of blinding.² These deficiencies render the reported findings unreliable. Clinical trials are similarly compromised, employing inappropriate outcome measures (e.g., ALSAQ40 for disease progression or survival), lacking proper control groups (relying on an ill-defined "worldwide reference" without adequate patient matching), and failing to conduct systematic safety monitoring.² Independent expert bodies, such as ALS Untangled, have explicitly stated that the data are "uninterpretable" and do not recommend the use of Endotherapia.⁴ The claims of significant life extension or "curative effects"¹ are not substantiated by rigorous, independently verified data.

In contrast, the evidence for **Palmitoylethanolamide (PEA)** is considerably more scientifically robust. Its mechanisms of action are well-characterized and supported by multiple studies.⁵ Its efficacy in chronic pain and other conditions is supported by higher-quality evidence, including meta-analyses and randomized controlled trials.⁵ While its direct efficacy in ALS is still under investigation in a formal, randomized controlled clinical trial (NCT02645461)¹³, preliminary findings suggest potential benefits on pulmonary function and acetylcholine receptor rundown.¹² PEA generally exhibits a favorable safety profile with minimal reported side effects.⁷

The most significant research gap identified is the complete absence of any studies on the combined use of Endotherapia and PEA. Furthermore, rigorous, independent, placebo-controlled trials are still needed to definitively establish PEA's efficacy in ALS. For Endotherapia, fundamental validation of its proposed mechanisms and well-designed clinical trials are critically lacking. This disparity in scientific credibility is crucial for any medical professional or patient considering these therapies. It indicates that PEA is a compound with a growing, scientifically-backed evidence base that warrants further investigation, whereas Endotherapia lacks the

fundamental scientific credibility to support its claims, making its use highly questionable and potentially risky. This distinction guides clinical recommendations and research priorities.

6. Conclusion and Future Research Directions

Conclusion of Key Findings

This comprehensive review unequivocally establishes that there is no scientific literature or evidence supporting the combined use of Endotherapia (GEMALS) and Palmitoylethanolamide (PEA) for treating Amyotrophic Lateral Sclerosis or any other medical condition. This represents the primary and most significant finding in response to the initial inquiry.

Endotherapia, also known as GEMALS, is a complex, multi-component therapeutic approach. Claims of its efficacy in ALS are based on studies that are widely recognized as methodologically flawed, rendering their results unreliable and uninterpretable by independent expert reviews. Its proposed mechanism, centered on bacterial involvement in ALS, remains unsubstantiated by scientific evidence, and its safety profile is largely unknown due to a lack of systematic monitoring. Furthermore, its composition includes fatty acids such as palmitic acid, which are known to possess pro-inflammatory properties, raising theoretical concerns about potential antagonistic effects if combined with anti-inflammatory agents.

In contrast, Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide with well-established anti-inflammatory, analgesic, and neuroprotective properties. Its mechanisms of action are clearly defined and supported by robust preclinical and clinical data. PEA has demonstrated efficacy in various chronic pain conditions and shown promising results in other neurodegenerative disorders like Frontotemporal Dementia. A rigorous, randomized controlled trial (NCT02645461) is currently investigating PEA's role in ALS in combination with Riluzole, indicating its potential as a legitimate therapeutic candidate. PEA generally exhibits a favorable safety profile with minimal reported side effects.

Recommendations for Future Research

Based on the current evidence, the following directions for future research are warranted:

- **For PEA in ALS:** Continued rigorous, well-designed, placebo-controlled clinical trials, such as NCT02645461, are essential to definitively establish its efficacy, optimal dosing, and long-term safety in ALS patients. Further mechanistic studies are also recommended to fully elucidate its precise neuroprotective pathways within the context of ALS pathophysiology.
- **For Endotherapia:** Before any further clinical consideration, independent and rigorous preclinical studies are critically needed to validate its proposed mechanisms of action. Should a plausible mechanism be established,

then well-designed, randomized, placebo-controlled clinical trials with appropriate outcome measures and systematic safety monitoring would be an indispensable prerequisite, as these are currently lacking.

- **For Combined Therapies:** Given the complex and multifactorial nature of ALS, combination therapies represent a promising avenue for future treatment strategies. However, any potential combination of PEA with other agents (including, hypothetically, components of Endotherapia) must be predicated on a strong preclinical rationale that demonstrates synergistic or additive effects. Such combinations would then require rigorous testing in well-controlled clinical trials to ensure both efficacy and safety. The theoretical conflict between PEA's established anti-inflammatory action and the pro-inflammatory nature of certain fatty acids within Endotherapia highlights the critical need for careful consideration of component interactions in any multi-drug approach to avoid unforeseen or counterproductive outcomes.

Works cited

1. Gemals, a new drug candidate, extends lifespan and improves ..., accessed July 18, 2025,
https://www.researchgate.net/publication/5424892_Gemals_a_new_drug_candidate_extends_lifespan_and_improves_electromyographic_parameters_in_a_rat_model_of_amyotrophic_lateral_sclerosis
2. ALS Untangled No.33 Endotherapia - ALS Untangled®, accessed July 18, 2025,
<https://www.alsuntangled.com/wp-content/uploads/2020/01/ALS-Untangled-No-33-Endotherapia.pdf>
3. (PDF) Endotherapia - ResearchGate, accessed July 18, 2025,
https://www.researchgate.net/publication/51024958_Endotherapia
4. Endotherapia - ALS Untangled®, accessed July 18, 2025,
<https://www.alsuntangled.com/review/endotherapia/>
5. Palmitoylethanolamide (PEA) - Alzheimer's Drug Discovery Foundation, accessed July 18, 2025,
https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Palmitoylethanolamide-Cognitive-Vitality-For-Researchers.pdf
6. How PEA Could Transform Your Endometriosis Pain Journey - Vida Integrated Health, accessed July 18, 2025,
<https://thinkvida.com/blog/how-pea-could-transform-your-endometriosis-pain-journey/>
7. PALMITOYLETHANOLAMIDE (PEA): Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews - WebMD, accessed July 18, 2025,
<https://www.webmd.com/vitamins/ai/ingredientmono-1596/palmitoylethanolamide-pea>
8. Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation - MDPI, accessed July 18, 2025,
<https://www.mdpi.com/2227-9059/13/6/1271>
9. HS and TS ACLS Algorithm Online Training, accessed July 18, 2025,
<https://www.aclsmedicaltraining.com/h-and-t/>
10. PEA and it's ACLS algorithm, accessed July 18, 2025,
<https://acls-algorithms.com/pea/>
11. Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain - PubMed, accessed July 18, 2025,

<https://pubmed.ncbi.nlm.nih.gov/39714723/>

12. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy | PNAS, accessed July 18, 2025,
<https://www.pnas.org/doi/10.1073/pnas.1600251113>
13. Study Details | Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS | ClinicalTrials.gov, accessed July 18, 2025,
<https://clinicaltrials.gov/study/NCT02645461>
14. Phase 2 study of palmitoylethanolamide combined with luteoline in frontotemporal dementia patients | Brain Communications | Oxford Academic, accessed July 18, 2025,
<https://academic.oup.com/braincomms/article/7/2/fcaf080/8052642>
15. Palmitoylethanolamide and Polydatin combination reduces inflammation and oxidative stress in vascular injury - PubMed, accessed July 18, 2025,
<https://pubmed.ncbi.nlm.nih.gov/28676456/>
16. The Neuroinflammatory and Neurotoxic Potential of Palmitic Acid Is Mitigated by Oleic Acid in Microglial Cells and Microglial-Neuronal Co-cultures - PubMed, accessed July 18, 2025, <https://pubmed.ncbi.nlm.nih.gov/33604780/>
17. The effect of palmitic acid on inflammatory response in macrophages: an overview of molecular mechanisms - Oregon Health and Science University - OHSU Library Search, accessed July 18, 2025,
https://librarysearch.ohsu.edu/discovery/fulldisplay?docid=cdi_unpaywall_primary_10_1007_s00011_019_01273_5&context=PC&vid=01ALLIANCE_OHSU:OHSU&lang=en&search_scope=Everything&adaptor=Primo%20Central&query=creator%2Cexact%2C%20TANTI%2C%20Jean-Fran%C3%A7ois%20%2CAND&facet=citedby%2Cexact%2Ccdi_FETCH-LOGICAL-c434t-85d1a4f9c84a5759eee1d8ec22c9788d8a25d2e254b9178780fcf9b5570bfa5e3&offset=0
18. Palmitic acid exerts pro-inflammatory effects on vascular smooth muscle cells by inducing the expression of C-reactive protein, inducible nitric oxide synthase and tumor necrosis factor- α - Spandidos Publications, accessed July 18, 2025,
<https://www.spandidos-publications.com/10.3892/ijmm.2014.1942>
19. The effect of palmitic acid on inflammatory response in macrophages: an overview of molecular mechanisms - PMC, accessed July 18, 2025,
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6813288/>
20. Poly(α - ω -lysine)-based nanomaterials for versatile biomedical applications: Current advances and perspectives - PubMed Central, accessed July 18, 2025,
<https://pmc.ncbi.nlm.nih.gov/articles/PMC7744653/>